May 15, 2020
May 15, 2020 – The U.S. FDA has approved a new indication for Rubraca® (rucaparib), manufactured by
Clovis Oncology. Rubraca is now indicated to treat adult patients who have
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
May 11, 2020
May 11, 2020 – The U.S. FDA has approved a new indication for Lynparza® (olaparib), manufactured by
AstraZeneca. Lynparza is now indicated for use in combination with bevacizumab
May 8, 2020
May 08, 2020 – By now, you may have heard of something called convalescent plasma therapy in the news. It’s a therapy that’s been in use for about a century.
May 8, 2020
May 7, 2020
May 7, 2020 – The U.S. FDA has approved TabrectaTM (capmatinib), manufactured by Novartis, to treat
adult patients who have metastatic non-small cell lung cancer (NSCLC) and
May 6, 2020
May 6, 2020 – The U.S. FDA has approved a new indication for Farxiga® (dapagliflozin) oral tablets,
manufactured by AstraZeneca. The drug is now indicated to reduce the risk of
May 4, 2020
May 4, 2020 – The U.S. FDA has approved Fensolvi® (leuprolide acetate), manufactured by Tolmar
Pharmaceuticals, to treat pediatric patients two years of age and older who
March 18, 2020
May 18, 2020 – The U.S FDA has approved a new indication for Tecentriq® (atezolizumab), manufactured
by Genentech, to provide initial